Most GHK-Cu myths stretch a real finding into a much bigger promise. Human studies have tested it on skin and wounds. Those results don't establish that injections make people younger, regrow hair, or work like a cream.
GHK-Cu is a peptide, a short chain of three building blocks called amino acids, bound to copper. Its biology explains the interest. The question is whether a particular preparation changes something that matters for people.
GHK-Cu myths: how the grades work
Supported means the evidence backs the claim as stated. Partly means a piece holds up. Not supported means the claim goes beyond the findings. Unknown means the question remains unanswered.
1. "GHK-Cu makes people younger."
Not supported. Skin measurements aren't proof of younger bodies. As of September 30, 2026, the day this article was written, a review published August 20, 2026 in Aesthetic Surgery Journal found 20 eligible studies of aesthetic uses: 18 in cells or animals and two randomized trials, which assign treatments by chance. It searched through March 2026 and considered GHK-Cu used alone. Those limits matter: the count isn't every GHK-Cu study ever conducted, and it doesn't establish an anti-aging benefit from injections. The GHK-Cu clinical evidence guide explains the review's findings.
2. "GHK-Cu resets 4,000 genes to younger settings."
Partly. The gene findings are real laboratory measurements; the claim about becoming younger goes further. Gene expression means how actively cells read a gene's instructions. Pickart's 2014 analysis in the Journal of Analytical Oncology estimated changes of at least 50% in 4,194 of 13,424 genes represented in its data. It used the Connectivity Map, a database of how cells grown in laboratories respond to compounds. The GHK data came from three sets of measurements in two types of cancer cells. GHK is the peptide portion of GHK-Cu. This was a computer analysis of cell responses, without measuring aging in treated people or rewriting their genetic code.
3. "GHK-Cu is proven in humans."
Partly. Human evidence exists for specific preparations and uses. In Mulder and colleagues' 1994 randomized trial in Wound Repair and Regeneration, a gel was applied to diabetic foot ulcers alongside organized wound care. The middle result for wound-area closure was 98.5% with the copper gel versus 60.8% with the comparison gel containing no active ingredient. That's the reduction in wound area, rather than the percentage of patients completely healed. A 2006 trial by Miller and colleagues in Archives of Facial Plastic Surgery had 13 completers after laser treatment. Satisfaction favored GHK-Cu skin care, but measured redness, wrinkles and overall skin quality did not differ between groups. Neither trial tested injections.
4. "A cream and an injection do the same thing."
Not supported. The route changes what needs testing. A cream must cross the skin barrier; an injection passes that barrier. In Hostynek and colleagues' 2011 study in Inflammation Research, researchers measured copper passing through isolated human skin over 48 hours. They didn't test living participants or compare creams with injections. Following copper doesn't show that it stays attached to the peptide or produces a benefit. A skin-application study cannot choose an injection amount, establish an equivalent effect, or answer long-term injection safety questions.
5. "GHK-Cu reliably regrows human hair."
Not supported. The familiar human-follicle finding belongs to a different peptide. Pyo and colleagues' 2007 study in Archives of Pharmacal Research tested AHK-Cu on human hair follicles kept alive outside the body. AHK-Cu replaces GHK-Cu's glycine with alanine, another amino acid. It isn't interchangeable evidence. Actual GHK-Cu hair research includes Liu and colleagues' Bioactive Materials study, published online in 2023, which tested a specially designed mixture on the skin of mice. Neither experiment establishes regrowth on a person's scalp. The GHK-Cu hair guide separates the molecules and study types.
6. "A GHK-Cu finding also proves a Glow blend works."
Not supported. A finding about one ingredient doesn't measure a complete blend. The August review evaluated GHK-Cu as a standalone intervention; it didn't establish results for Glow. Glow combines GHK-Cu with other peptides, so the whole preparation becomes the question. Even a positive result for each ingredient separately wouldn't show what their combination adds or how unwanted effects change. A compounded medication is prepared by a pharmacy for a prescription. FDA's compounding questions and answers explains that it doesn't verify these preparations' safety, effectiveness or quality before marketing. Ingredient research and assessment of a finished preparation answer different questions.
7. "It's natural, so injections have no safety questions."
Not supported. Finding a molecule in the body doesn't establish the safety of an added preparation. FDA's safety page, marked current as of April 22, 2026, identifies limited human safety data for compounded injectable GHK-Cu. It describes possible immune reactions related to peptide clumping or impurities. That is an identified concern, rather than a measured reaction rate or a prediction for every patient. The person's medical history and the pharmacy's preparation matter too. The GHK-Cu side-effects guide covers these questions in more detail.
8. "FDA has settled GHK-Cu's status."
Not supported. An ingredient review is different from review of a finished medicine. As of September 30, 2026, the day this article was written, FDA's nominations document, marked Updated May 14, 2026, lists non-injectable GHK-Cu in Category 1, meaning under evaluation for patient-specific compounding. The injectable nomination was withdrawn; it isn't the same entry. FDA's meeting page, current as of April 15, 2026, still plans a GHK-Cu discussion before the end of February 2027, without a specific date. A committee recommendation is advice to FDA. The GHK-Cu FDA review timeline explains those separate steps.
GHK-Cu through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. The pharmacy's dispensing requirements remain part of that decision.
What a provider can put behind the claims
A useful visit starts with the goal and the exact preparation being considered. The provider can explain which findings apply, what remains uncertain, and what follow-up could measure. For hair or skin concerns, the underlying cause matters alongside interest in a peptide.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If prescribed, a licensed U.S. compounding pharmacy dispenses the medication, with follow-up through the care team. That creates a clinical relationship. It doesn't turn a laboratory finding into a promised result.
